THE CANADIAN MARAVIROC RANDOMIZED CONTROLLED TRIAL TO AUGMENT REHABILITATION OUTCOMES AFTER STROKE (CAMAROS)

Registry ID

REB21-0258

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

GOVERNORS OF THE UNIVERSITY OF CALGARY

Start date

2024-08-12

Last update

2021-12-14

Conditions

• STROKE

Related clinical trials

• Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study
• THROMBOLYSIS DOMAIN (ACT WHEN) A MULTI-FACTORIAL, MULTI-ARM, MULTI-STAGE, RANDOMISED, GLOBAL ADAPTIVE PLATFORM TRIAL FOR STROKE (ACT-GLOBAL)
• A MULTICENTER, PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED-ENDPOINT, CONTROLLED, SINGLE-DOSE TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF NONO-42 IN PARTICIPANTS WITH ACUTE ISCHEMIC STROKE SELECTED FOR THROMBOLYSIS WITH OR WITHOUT ENDOVASCULAR THROMBECTOMY (ACT-42 TRIAL)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, FOR STROKE PREVENTION AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
• REEXAMINING HER CARDIOVASCULAR RISK - OTTAWA WOMEN'S LONGITUDINAL COHORT STUDY (HER CROWN)
• RFVIIA FOR ACUTE HEMORRHAGIC STROKE ADMINISTERED AT EARLIEST TIME (FASTEST)

View on source registry